MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
08.08.2022 - First patient dosed in Phase 1 study of MGD024 in CD123-positive hematologic malignanciesPlan to initiate MGC018 Phase 2/3 study in prostate cancer by year-endInitiates cost-saving measures through corporate restructuring with focus on key clinical ...
Source: wallstreet-online.de